정신과 질환에서의 임상 병기 및 조기 개입

키워드

참고문헌 (169)

1. McGorry PD, "Clinical staging of psychiatric disorders: a heuristic framework for choosing earlier, safer and more effective interventions", Aust N Z J Psychiatry, 40, pp.616~622 (2006)
2. McGorry P, "Biomarkers and clinical staging in psychiatry", World Psychiatry, 13, pp.211~223 (2014)
3. Eaton WW, "Prodromes and precursors:epidemiologic data for primary prevention of disorders with slow onset", Am J Psychiatry, 152, pp.967~972 (1995)
4. 노대영, "정신병 위험상태 : 관련된 문제와 향후 전망", 생물정신의학, 18(4), pp.203~209 (2011), 대한생물정신의학회
5. McGorry PD, "Issues for DSM-V: clinical staging: a heuristic pathway to valid nosology and safer, more effective treatment in psychiatry", Am J Psychiatry, 164, pp.859~860 (2007)
6. Wood SJ, "Neuroimaging and treatment evidence for clinical staging in psychotic disorders: from the at-risk mental state to chronic schizophrenia", Biol Psychiatry, 70, pp.619~625 (2011)
7. Lin A, "Clinical staging in severe mental disorder: evidence from neurocognition and neuroimaging", Br J Psychiatry Suppl, 54, pp.s11~s17 (2013)
8. Yung AR, "Mapping the onset of psychosis:the Comprehensive Assessment of At-Risk Mental States", Aust N Z J Psychiatry, 39, pp.964~971 (2005)
9. Yung AR, "Validation of “prodromal”criteria to detect individuals at ultra high risk of psychosis: 2 year follow-up", Schizophr Res, 105, pp.10~17 (2008)
10. Mathalon DH, "Challenges associated with application of clinical staging models to psychotic disorders", Biol Psychiatry, 70, pp.600~601 (2011)
11. Carpenter WT, "Anticipating DSM-V: should psychosis risk become a diagnostic class?", Schizophr Bull, 35, pp.841~843 (2009)
12. American Psychiatric Association, "Desk reference to the diagnostic criteria from DSM-5" (2013), American Psychiatric Publishing
13. Fava GA, "Staging: a neglected dimension in psychiatric classification", Acta Psychiatr Scand, 87, pp.225~230 (1993)
14. Cosci F, "Staging of mental disorders: systematic review", Psychother Psychosom, 82, pp.20~34 (2013)
15. Meares A, "The diagnosis of prepsychotic schizophrenia", Lancet, 1, pp.55~58 (1959)
16. Olin SC, "School teacher ratings predictive of psychiatric outcome 25 years later", Br J Psychiatry Suppl, 172, pp.7~13 (1998)
17. American Psychiatric Association, (1980), APA
18. Lieberman JA, "The early stages of schizophrenia:speculations on pathogenesis, pathophysiology, and therapeutic approaches", Biol Psychiatry, 50, pp.884~897 (2001)
19. Yung AR, "The prodromal phase of firstepisode psychosis: past and current conceptualizations", Schizophr Bull, 22, pp.353~370 (1996)
20. McGorry PD, "Clinical staging: a heuristic model for psychiatry and youth mental health", Med J Aust, 187, pp.2~ (2007)
21. Yung AR, "Prediction of psychosis: setting the stage", Br J Psychiatry, 191 (2007)
22. McGorry PD, "Clinical staging: a heuristic and practical strategy for new research and better health and social outcomes for psychotic and related mood disorders", Can J Psychiatry, 55, pp.486~497 (2010)
23. Agius M, "The staging model in schizophrenia, and its clinical implications", Psychiatr Danub (2010)
24. American Psychiatric Association, "Diagnostic and statistical manual of mental disorders: DSM-5" (2013), American Psychiatric Association
25. Yung AR, "Prediction of psychosis. A step towards indicated prevention of schizophrenia", Br J Psychiatry Suppl, 172, pp.14~20 (1998)
26. Takahashi T, "Altered depth of the olfactory sulcus in ultra high-risk individuals and patients with psychotic disorders", Schizophr Res, 153, pp.18~24 (2014)
27. Addington J, "North american prodrome longitudinal study: a collaborative multisite approach to prodromal schizophrenia research", Schizophr Bull, 33, pp.665~672 (2007)
28. McGorry PD, "Back to the future: predicting and reshaping the course of psychotic disorder", Arch Gen Psychiatry, 65, pp.25~ (2008)
29. Miller TJ, "Symptom assessment in schizophrenic prodromal states", Psychiatr Q, 70, pp.273~287
30. Gross G, "The “basic” symptoms of schizophrenia", Br J Psychiatry, 155, pp.21~25 (1989)
31. Schultze-Lutter F, "Predicting first-episode psychosis by basic symptom criteria", Clin Neuropsychiatry, 4, pp.11~22 (2007)
32. Fusar-Poli P, "Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk", Arch Gen Psychiatry, 69, pp.220~229 (2012)
33. Häfner H, "Causes and consequences of the gender difference in age at onset of schizophrenia", Schizophr Bull, 24, pp.99~113 (1998)
34. Niendam TA, "Exploring predictors of outcome in the psychosis prodrome:implications for early identification and intervention", uropsychol Rev, 19, pp.280~293 (2009)
35. Cannon TD, "Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America", Arch Gen Psychiatry, 65, pp.28~37 (2008)
36. Norman RM, "Duration of untreated psychosis:a critical examination of the concept and its importance", Psychol Med, 31, pp.381~400 (2001)
37. Marshall M, "Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review", Arch Gen Psychiatry, 62, pp.975~983 (2005)
38. Ruhrmann S, "Intervention in the at-risk state to prevent transition to psychosis", Curr Opin Psychiatry, 22, pp.177~183 (2009)
39. Morrison AP, "Cognitive therapy for the prevention of psychosis in people at ultra-high risk", Br J Psychiatry, 185, pp.291~297 (2004)
40. Kim KR, "Clinical efficacy of individual cognitive therapy in reducing psychiatric symptoms in people at ultrahigh risk for psychosis", Early Interv Psychiatry, 5, pp.174~178 (2011)
41. McGorry PD, "Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms", Arch Gen Psychiatry, 59, pp.921~928 (2002)
42. McGlashan TH, "Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis", Am J Psychiatry (2006)
43. Marder SR, "Fluphenazine vs Placebo Supplementation for Prodromal Signs of Relapse in Schizophrenia", Arch Gen Psychiatry, 51, pp.280~ (1994)
44. Correll CU, "Research in people with psychosis risk syndrome: a review of the current evidence and future directions", J Child Psychol Psychiatry, 51, pp.390~431 (2010)
45. Preti A, "Randomized-controlled trials in people at ultra high risk of psychosis: a review of treatment effectiveness", Schizophr Res, 123, pp.30~36 (2010)
46. van der Gaag M, "Preventing a first episode of psychosis:meta-analysis of randomized controlled prevention trials of 12 month and longer-term follow-ups", Schizophr Res, 149, pp.56~62 (2013)
47. Phillips LJ, "Randomized controlled trial of interventions for young people at ultra-high risk of psychosis:study design and baseline characteristics", Aust N Z J Psychiatry, 43, pp.818~829 (2009)
48. Angermeyer MC, "Public attitude towards psychiatric treatment", Acta Psychiatr Scand, 94, pp.326~336 (1996)
49. Lauber C, "Lay recommendations on how to treat mental disorders", Soc Psychiatry Psychiatr Epidemiol, 36, pp.553~556 (2001)
50. McGorry PD, "Intervention in individuals at ultra-high risk for psychosis: a review and future directions", J Clin Psychiatry, 70, pp.1206~1212 (2009)
51. Berger GE, "Ethyl-eicosapentaenoic acid in first-episode psychosis: a randomized, placebo-controlled trial", J Clin Psychiatry, 68, pp.1867~1875 (2007)
52. Amminger GP, "Long-chain ω-3fatty acids for indicated prevention of psychotic disorders:a randomized, placebo-controlled trial", Arch Gen Psychiatry, 67, pp.146~154 (2010)
53. Puri BK, "MRI and neuropsychological improvement in Huntington disease following ethyl-EPA treatment", Neuroreport, 13, pp.123~126 (2002)
54. Cornblatt BA, "Can antidepressants be used to treat the schizophrenia prodrome? Results of a prospective, naturalistic treatment study of adolescents", J Clin Psychiatry, 68, pp.1~478 (2007)
55. Fusar-Poli P, "Can antidepressants prevent psychosis?", Lancet, 370, pp.1746~1748 (2007)
56. Cantor-Graae E, "The contribution of social factors to the development of schizophrenia: a review of recent findings", Can J Psychiatry, 52, pp.277~ (2007)
57. Fava GA, "Prodromal stage of major depression", Early Interv Psychiatry, 1, pp.9~18 (2007)
58. Hetrick SE, "Early identification and intervention in depressive disorders: towards a clinical staging model", Psychother Psychosom, 77, pp.263~270 (2008)
59. Keller MB, "Implications of failing to achieve successful long-term maintenance treatment of recurrent unipolar major depression", Biol Psychiatry, 44, pp.348~360 (1998)
60. Andrews G, "Using epidemiological data to model efficiency in reducing the burden of depression", J Ment Health Policy Econ, 3, pp.175~186 (2000)
61. Fava GA, "Prodromal symptoms in primary major depressive disorder", J Affect Disord, 19, pp.149~152 (1990)
62. Lewinsohn PM, "Clinical implications of “subthreshold” depressive symptoms", J Abnorm Psychol, 109, pp.345~ (2000)
63. Wilcox HC, "Child and adolescent clinical features as forerunners of adult-onset major depressive disorder: retrospective evidence from an epidemiological sample", J Affect Disord, 82, pp.9~20 (2004)
64. Murphy JM, "Incidence of major depression:prediction from subthreshold categories in the Stirling County Study", J Affect Disord, 68, pp.251~259 (2002)
65. Hartlage SA, "Premenstrual dysphoric disorder and risk for major depressive disorder:a preliminary study", J Clin Psychiatry, 57, pp.1571~1578 (2001)
66. Fergusson DM, "Subthreshold depression in adolescence and mental health outcomes in adulthood", Arch Gen Psychiatry, 62, pp.66~72 (2005)
67. Cuijpers P, "Predicting the onset of major depression in subjects with subthreshold depression in primary care: a prospective study", Acta Psychiatr Scand, 111, pp.133~138 (2005)
68. Lewinsohn PM, "The prevalence and co-morbidity of subthreshold psychiatric conditions", Psychol Med, 34, pp.613~622 (2004)
69. Bond L, "Individual, family, school, and community risk and protective factors for depressive symptoms in adolescents: a comparison of risk profiles for substance use and depressive symptoms", Prev Sci, 6, pp.73~88 (2005)
70. Sadek N, "Subsyndromal symptomatic depression:a new concept", Depress Anxiety, 12, pp.30~39 (2000)
71. Jarrett RB, "Preventing recurrent depression using cognitive therapy with and without a continuation phase: a randomized clinical trial", Arch Gen Psychiatry, 58, pp.381~388 (2001)
72. Stice E, "A meta-analytic review of depression prevention programs for children and adolescents: factors that predict magnitude of intervention effects", J Consult Clin Psychol (2009)
73. Atlantis E, "An effective exercise-based intervention for improving mental health and quality of life measures: a randomized controlled trial", Prev Med, 39, pp.424~434 (2004)
74. Dunn AL, "Exercise treatment for depression: efficacy and dose response", Am J Prev Med, 28, pp.1~8 (2005)
75. Murphy GE, "Cognitive behavior therapy, relaxation training, and tricyclic antidepressant medication in the treatment of depression", Psychol Rep, 77, pp.403~420 (1995)
76. Reynolds WM, "A comparison of cognitivebehavioral therapy and relaxation training for the treatment of depression in adolescents", J Consult Clin Psychol, 54, pp.653~ (1986)
77. Dowrick C, "Problem solving treatment and group psychoeducation for depression: multicentre randomised controlled trial", BMJ, 321, pp.1450~ (2000)
78. Ruini C, "Well-being therapy in school settings: a pilot study", Psychother Psychosom, 75, pp.331~336 (2006)
79. Ryff CD, "Psychological wellbeing and ill-being: do they have distinct or mirrored biological correlates?", Psychother Psychosom, 75, pp.85~95 (2006)
80. In-Albon T, "Psychotherapy of childhood anxiety disorders: A meta-analysis", Psychother Psychosom, 76, pp.15~24 (2006)
81. Parker G, "Early onset depression:the relevance of anxiety", Soc Psychiatry Psychiatr Epidemiol, 32, pp.30~37 (1997)
82. Walkup JT, "Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety", N Engl J Med, 359, pp.2753~2766 (2008)
83. Calear AL, "Systematic review of schoolbased prevention and early intervention programs for depression", J Adolesc (2010)
84. Cohen D, "Should the use of selective serotonin reuptake inhibitors in child and adolescent depression be banned?", Psychother Psychosom, 76, pp.5~14 (2006)
85. Dubicka B, "Suicidal behaviour in youths with depression treated with new-generation antidepressants", Br J Psychiatry, 189, pp.393~398 (2006)
86. Friedman RA, "Expanding the black boxdepression, antidepressants, and the risk of suicide", N Engl J Med, 356, pp.2343~2346 (2007)
87. Hammad TA, "Suicidality in pediatric patients treated with antidepressant drugs", Arch Gen Psychiatry, 63, pp.332~339 (2006)
88. Hetrick S, "Selective serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and adolescents", Cochrane Database Syst Rev, 3 (2007)
89. Rickwood D, "Young people’s help-seeking for mental health problems", AeJAMH, 4, pp.218~251 (2005)
90. Picardi A, "A randomised controlled trial of the effectiveness of a program for early detection and treatment of depression in primary care", J Affect Disord, 198, pp.96~101 (2016)
91. Wright A, "Development and evaluation of a youth mental health community awareness campaign - The Compass Strategy", Bmc Public Health, 6 (2006)
92. Verduijn J, "Clinical staging of major depressive disorder: an empirical exploration", J Clin Psychiatry, 76, pp.1200~1208 (2015)
93. Thase ME, "When at first you don’t succeed:Sequential strategies for antidepressant nonresponders", J Clin Psychiatry, 58, pp.23~29 (1997)
94. Souery D, "Treatment resistant depression:methodological overview and operational criteria", Eur Neuropsychopharmacol, 9, pp.83~91 (1999)
95. Fava M, "Diagnosis and definition of treatment-resistant depression", Biol Psychiatry, 53, pp.649~659 (2003)
96. Berlim MT, "Definition, assessment, and staging of treatment-resistant refractory major depression:a review of current concepts and methods", Can J Psychiatry, 52, pp.46~54 (2007)
97. Petersen T, "Empirical testing of two models for staging antidepressant treatment resistance", J Clin Psychopharmacol, 25, pp.336~341 (2005)
98. Fekadu A, "The maudsley staging method for treatment-resistant depression", J Clin Psychiatry, 70, pp.952~957 (2009)
99. Fekadu A, "A multidimensional tool to quantify treatment resistance in depression: the Maudsley staging method", J Clin Psychiatry, 70, pp.177~184 (2009)
100. Carlson GA, "The stages of mania: a longitudinal analysis of the manic episode", Arch Gen Psychiatry, 28, pp.221~228 (1973)
101. Berk M, "Setting the stage: from prodrome to treatment resistance in bipolar disorder", Bipolar Disord, 9, pp.671~678 (2007)
102. Berk M, "The potential utility of a staging model as a course specifier: a bipolar disorder perspective", J Affect Disord, 100, pp.279~281 (2007)
103. McNamara RK, "Preventative strategies for early-onset bipolar disorder: towards a clinical staging model", CNS drugs, 24, pp.983~996 (2010)
104. Kapczinski F, "Clinical implications of a staging model for bipolar disorders", Expert Rev Neurother, 9, pp.957~966 (2009)
105. Gama CS, "Staging and neuroprogression in bipolar disorder: a systematic review of the literature", Rev Bras Psiquiatr, 35, pp.70~74 (2013)
106. Grande I, "Staging bipolar disorder: clinical, biochemical, and functional correlates", Acta Psychiatr Scand, 129, pp.437~444 (2014)
107. Fava GA, "Subclinical symptoms in mood disorders:pathophysiological and therapeutic implications", Psychol Med, 29, pp.47~61 (1999)
108. Lewandowski KE, "Evolution of neuropsychological dysfunction during the course of schizophrenia and bipolar disorder", Psychol Med, 41, pp.225~241 (2011)
109. Ratheesh A, "Instruments that prospectively predict bipolar disorder - A systematic review", J Affect Disord, 179, pp.65~73 (2015)
110. Depue RA, "General behavior inventory identification of unipolar and bipolar affective conditions in a nonclinical university population", J Abnorm Psychol, 98, pp.117~ (1989)
111. Reichart CG, "The use of the GBI as predictor of bipolar disorder in a population of adolescent offspring of parents with a bipolar disorder", J Affect Disord, 89, pp.147~155 (2005)
112. Eckblad M, "Development and validation of a scale for hypomanic personality", J Abnorm Psychol, 95, pp.214~222 (1986)
113. Kwapil TR, "A longitudinal study of high scorers on the hypomanic personality scale", J Abnorm Psychol, 109, pp.222~226 (2000)
114. Bordin IA, "Child Behavior Checklist (CBCL),Youth Self-Report (YSR) and Teacher’s Report Form(TRF): an overview of the development of the original and Brazilian versions", Cad Saude Publica, 29, pp.13~28 (2013)
115. Meyer SE, "Long-term outcomes of youth who manifested the CBCL-Pediatric Bipolar Disorder phenotype during childhood and", or adolescence, 2009, pp.113, 227~235
116. Papachristou E, "Child Behavior Checklist-Mania Scale (CBCL-MS): Development and evaluation of a population-based screening scale for bipolar disorder", PloS one, 8, pp.e69459~ (2013)
117. Weissman MM, "Brief screening for family psychiatric history: the family history screen", Arch Gen Psychiatry, 57, pp.675~682 (2000)
118. Carver CS, "Behavioral-inhibition, behavioral activation, and affective responses to impending reward and punishment - the Bis Bas Scales", J Pers Soc Psychol, 67, pp.319~333 (1994)
119. Benarous X, "Early interventions for youths at high risk for bipolar disorder:a developmental approach", Eur Child Adolesc Psychiatry, 25, pp.217~233 (2016)
120. Pfennig A, "Psychotherapeutic interventions in individuals at risk of developing bipolar disorder:a systematic review", Early Interv Psychiatry, 8, pp.3~11 (2014)
121. Nadkarni RB, "Clinical course of children with a depressive spectrum disorder and transient manic symptoms", Bipolar Disord, 12, pp.494~503 (2010)
122. Miklowitz DJ, "Early psychosocial intervention for youth at risk for bipolar I or II disorder:a one-year treatment development trial", Bipolar Disord, 13, pp.67~75 (2011)
123. Miklowitz DJ, "Early intervention for symptomatic youth at risk for bipolar disorder: a randomized trial of family-focused therapy", J Am Acad Child Adolesc Psychiatry, 52, pp.121~131 (2013)
124. Goldstein TR, "Early intervention for adolescents at high risk for the development of bipolar disorder: pilot study of Interpersonal and Social Rhythm Therapy (IPSRT)", Psychotherapy (Chic), 51, pp.180~189 (2014)
125. Geller B, "Lithium for prepubertal depressed children with family history predictors of future bipolarity:a double-blind, placebo-controlled study", J Affect Disord, 51, pp.165~175 (1998)
126. Chang KD, "Divalproex monotherapy in the treatment of bipolar offspring with mood and behavioral disorders and at least mild affective symptoms", J Clin Psychiatry, 64, pp.936~942 (2003)
127. Findling RL, "Double-blind, placebo-controlled trial of divalproex monotherapy in the treatment of symptomatic youth at high risk for developing bipolar disorder", J Clin Psychiatry, 68, pp.781~788 (2007)
128. DelBello MP, "A 12-week single-blind trial of quetiapine for the treatment of mood symptoms in adolescents at high risk for developing bipolar I disorder", J Clin Psychiatry, 68, pp.789~795 (2007)
129. Sarris J, "Omega-3 for bipolar disorder: meta-analyses of use in mania and bipolar depression", J Clin Psychiatry, 73, pp.81~86 (2012)
130. Prichard JC, "A treatise on insanity and other disorders affecting the mind" (1837), E. L. Carey & A. Hart
131. Kral VA, "Senescent forgetfulness: benign and malignant", Can Med Assoc J, 86, pp.257~260 (1962)
132. Hughes CP, "A new clinical scale for the staging of dementia", Br J Psychiatry, 140, pp.566~572 (1982)
133. Reisberg B, "The Global Deterioration Scale for assessment of primary degenerative dementia", Am J Psychiatry, 139, pp.1136~1139 (1982)
134. McKhann G, "Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease", Neurology, 34, pp.939~944 (1984)
135. Alzheimers Dement, "Introduction to the recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease", Alzheimers Dement, 7, pp.257~262 (2011)
136. Sperling RA, "Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease", Alzheimers Dement, 7, pp.280~292 (2011)
137. Li JQ, "Risk factors for predicting progression from mild cognitive impairment to Alzheimer’s disease: a systematic review and meta-analysis of cohort studies", J Neurol Neurosurg Psychiatry (2015)
138. Murray J, "FDG and amyloid pet in cognitively normal individuals at risk for late-onset Alzheimer’s disease", Adv J Mol Imaging, 4, pp.15~26 (2014)
139. Belleville S, "Detecting early preclinical Alzheimer’s disease via cognition, neuropsychiatry, and neuroimaging:qualitative review and recommendations for testing", J Alzheimers Dis, 42(4), pp.S375~S382 (2014)
140. Espinosa A, "A longitudinal followup of 550 mild cognitive impairment patients: evidence for large conversion to dementia rates and detection of major risk factors involved", J Alzheimers Dis, 34, pp.769~780 (2013)
141. Ewers M, "Prediction of conversion from mild cognitive impairment to Alzheimer’s disease dementia based upon biomarkers and neuropsychological test performance", Neurobiol Aging, 33, pp.1203~1214 (2012)
142. Hua X, "Tensor-based morphometry as a neuroimaging biomarker for Alzheimer’s disease: An MRI study of 676 AD, MCI, and normal subjects", Neuroimage, 43, pp.458~469 (2008)
143. Desikan RS, "Automated MRI measures predict progression to Alzheimer’s disease", Neurobiol Aging, 31, pp.1364~1374 (2010)
144. Kovacevic S, "Highthroughput, Fully Automated Volumetry for Prediction of MMSE and CDR Decline in Mild Cognitive Impairment", Alzheimer Dis Assoc Disord, 23, pp.139~145 (2009)
145. Risacher SL, "Baseline MRI predictors of conversion from MCI to probable AD in the ADNI cohort", Curr Alzheimer Res, 6, pp.347~361 (2009)
146. Walhovd KB, "Combining MR Imaging, Positron-Emission Tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease", Am J Neuroradiol, 31, pp.347~354 (2010)
147. Chou YY, "Mapping correlations between ventricular expansion and CSF amyloid and tau biomarkers in 240 subjects with Alzheimer’s disease, mild cognitive impairment and elderly controls", Neuroimage, 46, pp.394~410 (2009)
148. Chou YY, "Ventricular maps in 804 ADNI subjects:correlations with CSF biomarkers and clinical decline", Neurobiol Aging, 31, pp.1386~1400 (2010)
149. Madsen SK, "3D maps localize caudate nucleus atrophy in 400 Alzheimer’s disease, mild cognitive impairment, and healthy elderly subjects", Neurobiol Aging, 31, pp.1312~1325 (2010)
150. Chen KW, "Characterizing Alzheimer’s disease using a hypometabolic convergence index", Neuroimage, 56, pp.52~60 (2011)
151. 김병수, "다시 보는 알츠하이머병의 아밀로이드 가설", 생물치료정신의학, 20(3), pp.173~186 (2014), 대한생물치료정신의학회
152. Hardy J, "The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics", Science, 297, pp.353~356 (2002)
153. Pike KE, "Cognition and beta-amyloid in preclinical Alzheimer’s disease: data from the AIBL study", Neuropsychologia, 49, pp.2384~2390 (2011)
154. AV-45 positron emission tomography in Chinese population, "PLoS One", 2013, e58974~
155. Camus V, "Using PET with 18F-AV-45 (florbetapir)to quantify brain amyloid load in a clinical environment", Eur J Nucl Med Mol Imaging, 39, pp.621~631 (2012)
156. F 18), "J Nucl Med", 2010, 913~920
157. Rabinovici GD, "Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo", Behav Neurol, 21, pp.117~128 (2009)
158. Rowe CC, "Imaging beta-amyloid burden in aging and dementia", Neurology, 68, pp.1718~1725 (2007)
159. flutemetamol amyloid positron emission tomography in preclinical and symptomatic Alzheimer’s disease: specific detection of advanced phases of amyloid-β pathology, "Alzheimers Dement", 2015, 975~985
160. De Craen AJ, "Meta-analysis of nonsteroidal antiinflammatory drug use and risk of dementia", Am J Epidemiol, 161, pp.114~120 (2005)
161. Group AR, "Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial", Neurology, 68, pp.1800~1808 (2007)
162. Boothby LA, "Vitamin C and vitamin E for Alzheimer’s disease", Ann Pharmacother, 39, pp.2073~2080 (2005)
163. Miller ER, "Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality", Ann Intern Med, 142, pp.37~46 (2005)
164. Patterson C, "Diagnosis and treatment of dementia: 1. Risk assessment and primary prevention of Alzheimer disease", CMAJ, 178, pp.548~556 (2008)
165. Shumaker SA, "Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women’s Health Initiative Memory Study", JAMA, 291, pp.2947~2958 (2004)
166. Daviglus ML, "National Institutes of Health State-of-the-Science Conference statement: preventing alzheimer disease and cognitive decline", Ann Intern Med, 153, pp.176~181 (2010), Ann Intern Med
167. Snyder HM, "Alzheimer’s disease research in the context of the national plan to address Alzheimer’s disease", Mol Aspects Med, 43-44, pp.16~24 (2015)
168. Khachaturian ZS, "Perspective on the “2014 Report on the Milestones for the US National Plan to Address Alzheimer’s Disease”", Alzheimers Dement, 10, pp.S265~S268 (2014)
169. Alzheimer’s Association Expert Advisory Workgroup on N, "Workgroup on NAPA’s scientific agenda for a national initiative on Alzheimer’s disease", Alzheimers Dement, 8, pp.357~371 (2012)

관련 논문AI추천